Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Product › Details

Nubeqa®

Products Next higher product group darolutamide (ODM-201 / BAY-1841788)
Period Status 2019-07-31 registration start
Organisation Organisation Bayer HealthCare (Group)
  Group Bayer (Group)
Document Source Bayer AG. (7/31/19). "Press Release: U.S. FDA Approves Darolutamide, a New Treatment for Men with Non-metastatic Castration-resistant Prostate Cancer [Not intended for U.S. and UK Media]". Berlin.
     

   
Record changed: 2020-02-12

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

More documents for darolutamide (ODM-201 / BAY-1841788)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top